Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue: +79.6%
EPS: +26.9%
Free cash flow: +95.4%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

112.38 7.36 +7.01%

Follow RYTM

Alert me

Market cap: $7.3B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 6/9
Altman Z: 15.89
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. (RYTM) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Rhythm Pharmaceuticals, Inc. (RYTM) trades at a P/B ratio of 81.4×. Over the past ten years it has ranged from 0.0× (September 2025) to 368× (November 2024); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RYTM/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Rhythm Pharmaceuticals, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RYTM/metrics/pb-ratio">Rhythm Pharmaceuticals, Inc. (RYTM) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	50.0×	(68.17%)
FY2024	157×	924.90%
FY2023	15.3×	171.43%
FY2022	5.6×	224.25%
FY2021	1.7×	—

Period	P/B ratio	Change
Sep 2026	74.7×	1.06%
Jun 2026	74.0×	53.75%
Mar 2026	48.1×	(3.83%)
Dec 2025	50.0×	11.23%
19 more quarters	Free account

Against its own ten years

Low 0.0× High 368×

Ten-year median 4.8×

Current reading's percentile 91

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
ORKA Oruka Therapeutics, Inc. compare	5.5×
PRAX Praxis Precision Medicines, Inc. compare	5.7×
CORT Corcept Therapeutics Incorporated compare	9.2×
IONS Ionis Pharmaceuticals, Inc. compare	14.6×
ABVX Abivax SA Sponsored ADR compare	15.8×
ARWR Arrowhead Pharmaceuticals, Inc. compare	17.7×
AXSM Axsome Therapeutics, Inc. compare	64.2×
RYTM Rhythm Pharmaceuticals, Inc.	81.4×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Rhythm Pharmaceuticals, Inc. (RYTM) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RYTM

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RYTM

Stockrow Weekly